[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100201442":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":49,"collaborators":19,"id":51,"slug":19,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Affiliated Hospital to Academy of Military Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adenovirus-transfected DC + CIK","EXPERIMENTAL","Adenovirus-transfected autologous DCs + CIK cells",[13],"Biological: Adenovirus-transfected DC + CIK",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Adenovirus-transfected autologous DC vaccine plus CIK cells",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Chen Hu, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Bin Zhang, M.D., Ph.D.","CONTACT","+86-010-6694-7125","zb307ctc@163.com",[31],{"facility":32,"status":33,"city":34,"state":19,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Department of Hematopoietic Stem Cell Transplantation","RECRUITING","Beijing","100071","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":19,"email":48},"Dan ho Wang, M.M.","+86-010-6694-7102","wangdh307@sina.com",{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100201442",false,"NCT01898663","DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML","Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ\u002FⅡ Study","Inclusion Criteria:\n\n* Consistent with the diagnosis of AML\n* Age≥18 years at time of consent\n* KPS(Karnofsky Performance Scale) ≥70\n* Patient's written informed consent\n* No steroid therapy within 4 weeks of first DC vaccination\n* Stable disease, complete response and partial response(WHO, RECIST)\n* Predicted survival≥3 months\n\nExclusion Criteria:\n\n* Serious dysfunction of vital organs(heart, liver or kidney)\n* Received organ transplantation\n* Patients with other malignancies or brain metastases\n* History of autoimmune diseases\n* Pregnant and breast-feeding patient\n* Active or chronic infectious diseases\n* History of allergy or hypersensitivity to study product excipients\n* Currently participating in another clinical trial\n* Received chemotherapy, radiotherapy, immune inhibitor (such as corticosteroid) or other immunotherapy (such as vaccine) during prior 4 weeks\n* Unfit for participating in this clinical trial in investigators' opinions","ALL","18 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE1","PHASE2","The aim of this Phase Ⅰ\u002FⅡ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.",[68],"High-risk Soft Tissue Sarcoma","2024-06-28",{"date":71,"type":72},"2024-07-01","ACTUAL",{"date":74,"type":19},"2013-06",{"date":76,"type":61},"2024-12-30",{"name":5,"class":6},1]